
Gilles Kaplanski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2822418/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hydroxychloroquine-related hyperpigmentation. Rheumatology, 2022, 61, 873-873.	1.9	0
2	Mast cells drive pathologic vascular lesions in Takayasu arteritis. Journal of Allergy and Clinical Immunology, 2022, 149, 292-301.e3.	2.9	7
3	Considering the level of myositis-specific autoantibodies could improve the precision of multiplex assay : lesson from patients with multiple positive results. Seminars in Arthritis and Rheumatism, 2022, 52, 151871.	3.4	1
4	Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study Autoimmunity Reviews, 2021, 20, 102726.	5.8	18
5	Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19. Blood Advances, 2021, 5, 628-634.	5.2	96
6	French recommendations for the management of Behçet's disease. Orphanet Journal of Rare Diseases, 2021, 16, 352.	2.7	27
7	Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e503-e505.	0.4	3
8	Discrimination of COVIDâ€19 From Inflammationâ€Induced Cytokine Storm Syndromes Using Diseaseâ€Related Blood Biomarkers. Arthritis and Rheumatology, 2021, 73, 1791-1799.	5.6	36
9	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatology, The, 2021, 3, e690-e697.	3.9	121
10	Axial Articular Manifestations in Primary Sjögren Syndrome: Association With Spondyloarthritis. Journal of Rheumatology, 2020, 48, jrheum.200189.	2.0	4
11	Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18951-18953.	7.1	173
12	Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood, 2020, 136, 353-361.	1.4	35
13	Evolution Toward Severe Covid-19 From Biological Monitoring to Therapeutic Considerations. Frontiers in Immunology, 2020, 11, 562038.	4.8	0
14	Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opinion on Biological Therapy, 2019, 19, 477-490.	3.1	51
15	Interleukinâ€18: Biological properties and role in disease pathogenesis. Immunological Reviews, 2018, 281, 138-153.	6.0	383
16	Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia. Journal of Clinical Lipidology, 2018, 12, 883-887.	1.5	7
17	Pathogenesis of ANCA-associated vasculitis: An update. Autoimmunity Reviews, 2016, 15, 704-713.	5.8	75